文献速递前列腺癌

PSMA PET靶向前列腺穿刺活检用于前列腺癌诊断:多中心队列初步经验

PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience From a Multicenter Cohort.
PubMed 文献 · Urology · 2024-10-18

这项由欧洲泌尿外科学会青年学术泌尿医师前列腺癌组支持的多中心观察性队列研究,在6家欧洲三级中心纳入72例患者,评估PSMA-PET/CT引导下前列腺穿刺活检的前列腺癌及临床有意义前列腺癌检出率,并与标准活检和MRI引导活检比较。

要点

  • PSMA-PET/CT引导活检对前列腺癌和临床有意义前列腺癌的检出率显著高于标准活检。
  • PSMA-PET/CT引导活检的检出率未超过MRI引导活检(差异无统计学意义)。
  • PSMA-PET/CT引导活检在初次活检患者中表现优于重复活检患者。

核心结论

  • 真实世界数据表明PSMA-PET/CT引导活检在前列腺癌诊断中具有潜力。
  • 在疑似高危疾病的初次活检患者中,可考虑使用PSMA-PET/CT靶向活检。
  • 在重复活检背景下,PSMA-PET/CT靶向活检可能优于标准活检。

研究设计与样本

  • 多中心观察性队列研究,由欧洲泌尿外科学会青年学术泌尿医师前列腺癌组支持,在6家欧洲三级中心开展。
  • 共纳入72例患者,所有患者均接受PSMA引导活检(认知/融合方式),可联合或不联合MRI引导活检和/或标准活检。

主要发现

  • PSMA-PET/CT所示主病灶的解剖位置与临床有意义前列腺癌的位置显著相关,尤其在初次活检队列中。
  • PSMA-PET/CT引导活检的前列腺癌检出率为0.40 ± 0.43,标准活检为0.23 ± 0.29,两者差异有统计学意义(P <.05)。
  • PSMA-PET/CT引导活检的临床有意义前列腺癌检出率为0.36 ± 0.44,标准活检为0.21 ± 0.30,两者差异有统计学意义(P <.05)。
  • PSMA-PET/CT引导活检的前列腺癌检出率为0.40 ± 0.43,MRI引导活检为0.47 ± 0.44,两者差异无统计学意义(P >.05)。
  • PSMA-PET/CT引导活检的临床有意义前列腺癌检出率为0.36 ± 0.44,MRI引导活检为0.47 ± 0.34,两者差异无统计学意义(P >.05)。

临床怎么用

  • 作者认为,在疑似高危疾病的初次活检患者中,可考虑使用PSMA-PET/CT靶向活检。
  • 作者认为,在重复活检背景下,PSMA-PET/CT靶向活检可能优于标准活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the initial experience with PSMA-PET/CT-guided biopsy in European referral centres. METHODS: This multicenter observational cohort study was endorsed by the Young Academic Urologist (YAU) Prostate Cancer Group of the EAU and conducted across 6 tertiary-level European centres. PSMA-guided biopsies were carried out in a cognitive/fusion manner for all the recruited patients with or without MRI-guided biopsies and/or standard biopsy (SB). PCa and clinical significant PCa (csPCA) detection rate (DR) at prostate biopsy was assessed. Uni- and multivariable models were employed to identify features related to csPCA. RESULTS: Overall, 72 patients were recruited. The topographic location of the dominant lesion depicted by PSMA PET/CT was significantly associated with the location of csPCa, especially in the biopsy naïve cohort. The DR for PCa and csPCa of PSMA-PET/CT-guided biopsies was significantly higher than SB (0.40 ± 0.43 vs 0.23 ± 0.29, and 0.36 ± 0.44 vs 0.21 ± 0.30, respectively, both P <.05) but did not surpass MRI-guided biopsies (0.40 ± 0.43 vs 0.47 ± 0.44, and 0.36 ± 0.44 vs 0.47 ± 0.34, respectively, both P >.05). PSMA-PET/CT-guided biopsy performed better in the biopsy naïve than in the repeated biopsy setting. A SUVmax cut-off value equal to 4.8 provided the best results for detecting csPCa. CONCLUSION: Our real-world data illustrate the potentialities of PSMA-PET/CT-guided biopsy in diagnosing PCa. Specifically, in biopsy naïve patients with suspicion of high-risk disease, the use of PSMA-PET/CT-targeted biopsy can be considered. Additionally, in the context of repeated biopsies, a PSMA-PET/CT target biopsy might be advisable over the SB.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Checcucci E, Bauckneht M, Cisero E, et al. PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience From a Multicenter Cohort. Urology. 2024. PMID: 39426743. doi:10.1016/j.urology.2024.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。